Cell coding company bit.bio announces an expansion to its product portfolio to accelerate research into neurodegenerative diseases. Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS)
Data presented on human muscle, CNS and immune cells and associated disease models Cells have been developed with the company's opti-oxTM precision cellular reprogramming technology
bit.bio’s new ioGlutamatergic Neurons HTT50CAG/WT provide a human, cell-based, in vitro model of Huntington’s Disease (HD) that accurately reflects the disease genotype. Offering industry-leading consistency and scalability, this first product from the new ioDisease Model portfolio has been developed to support key applications within drug discovery including target identification and high-throughput screening.